AbbVie (ABBV)

The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of $436.27 billion. Buying

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-G...

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for. AbbVie beat analysts’...

But is that performance sustainable?

AbbVie still looks like a compelling buy at its all-time high.

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

Both have very promising futures.

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

There are plenty of reasons to love these companies.

When quality goes on sale, it's time to back up the truck.

It looks like a great buy-and-hold option.

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

There's no need to panic.

They can help stabilize your portfolio in these otherwise volatile times.

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basis producing an average annual return of 14.83%. Currently, AbbVie has a market capitalization of $454.46 billion.

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

Drug pricing matters, but pipelines matter even more.

You need to look beyond the tech sector to find great dividend stocks for the long term.

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.